• Aprea Therapeutics’ third-quarter 2026 net loss widened 62% year over year to $4.81 million.
• Research and development expenses more than doubled to $3.34 million, primarily due to higher ACESOT-1051 trial spending.
• Cash and cash equivalents totaled $37.85 million at September 30, 2026, with cash runway expected into the first quarter of 2028.
• Updated interim APR-1051 Phase 1 results will be presented November 20, 2026; Part 2 dose selection remains targeted for first-half 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040830PRIMZONEFULLFEED9869852) on November 04, 2026, and is solely responsible for the information contained therein.